Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.
Cystic Fibrosis – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 29, 27, 60 and 30 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.
Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
REQUEST FOR A SAMPLE REPORT:
– The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
– The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
BUY THIS REPORT ONLINE:
4D Molecular Therapeutics Inc
Advanced Inhalation Therapies (AIT) Ltd
Aeolus Pharmaceuticals Inc
AmpliPhi Biosciences Corp
Arch Biopartners Inc
Arcturus Therapeutics Ltd
Aridis Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Calithera Biosciences Inc
Catabasis Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Cyclacel Pharmaceuticals Inc
Cyclenium Pharma Inc
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
Enterprise Therapeutics Ltd
Errant Gene Therapeutics LLC
Evaxion Biotech ApS
Generation Bio Corp
Grupo Praxis Pharmaceutical SA
Helperby Therapeutics Group Ltd
Homology Medicines, Inc.
Horizon Pharma Plc
ID Pharma Co Ltd
Idorsia Pharmaceutical Ltd
Immun System IMS AB
Ionis Pharmaceuticals Inc
JHL Biotech Inc
Johnson & Johnson
Kyorin Pharmaceutical Co Ltd
Lamellar Biomedical Ltd
Laurent Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc
Onspira Therapeutics Inc
Paranta Biosciences Ltd
Parion Sciences Inc
PhaseBio Pharmaceuticals Inc
ProQR Therapeutics NV
Protalix BioTherapeutics Inc
Proteostasis Therapeutics Inc
ReveraGen BioPharma Inc
Santhera Pharmaceuticals Holding AG
Sequoia Sciences Inc
Translate Bio Inc
Vanda Pharmaceuticals Inc
Verona Pharma Plc
Vertex Pharmaceuticals Inc
Get in touch with us:
Ritesh Tiwari, Director